Brainstorm Cell Therapeutics

$4.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (+2.22%) Today
+$0.05 (+1.20%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BCLI and other stocks, options, and ETFs commission-free!

About BCLI

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ. The listed name for BCLI is Brainstorm Cell Therapeutics Inc. Common Stock.

CEO
Chaim Lebovits
Employees
40
Headquarters
New York, New York
Founded
2000
Market Cap
157.21M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.46M
High Today
$4.21
Low Today
$4.05
Open Price
$4.20
Volume
533.44K
52 Week High
$17.95
52 Week Low
$3.80

BCLI Earnings

-$0.43
-$0.29
-$0.14
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market

You May Also Like

DFH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure